Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Guangzhou Innogen Pharmaceutical Group Co EBITDA Margin % Related Terms
Guangzhou Innogen Pharmaceutical Group Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Innogen Pharmaceutical Group Co EBITDA Margin % Chart
Guangzhou Innogen Pharmaceutical Group Co Annual Data
Trend
Dec23
Dec24
Dec25
EBITDA Margin %
0.00
0.00
-250.68
Guangzhou Innogen Pharmaceutical Group Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
EBITDA Margin %
0.00
0.00
0.00
-208.91
-282.09
HKSE:02591 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Guangzhou Innogen Pharmaceutical Group Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Innogen Pharmaceutical Group Co EBITDA Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a EBITDA Margin % of -282.09% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Guangzhou Innogen Pharmaceutical Group Co and its competitors. According to the industry distribution chart, Guangzhou Innogen Pharmaceutical Group Co ranks #608 out of 942 companies in the Biotechnology industry, placing it in the top 64.5%.
Is Guangzhou Innogen Pharmaceutical Group Co's EBITDA Margin % too high?
Guangzhou Innogen Pharmaceutical Group Co's current EBITDA Margin % is -282.09%. Based on the distribution chart, Guangzhou Innogen Pharmaceutical Group Co ranks #608 out of 942 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Guangzhou Innogen Pharmaceutical Group Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Innogen Pharmaceutical Group Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Guangzhou Innogen Pharmaceutical Group Co ranks #608 out of 942 companies for EBITDA Margin %. This places Guangzhou Innogen Pharmaceutical Group Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Guangzhou Innogen Pharmaceutical Group Co and its competitors. Guangzhou Innogen Pharmaceutical Group Co's current EBITDA Margin % is -282.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Innogen Pharmaceutical Group Co stock overvalued right now?
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a current EBITDA Margin % of -282.09%. The current EBITDA Margin % is -282.09%. Guangzhou Innogen Pharmaceutical Group Co's overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591), the current EBITDA Margin % is -282.09% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize, a humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates namely YN014, YN401, YN209, YN202,YN203 targeting diabetes and other metabolic diseases.
9GF Score
Get the complete analysis for HKSE:02591
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02591 has been successfully added to your 
